Petrovax Pharm reports 25% growth in export sales in H1 2025

Russian biopharmaceutical company Petrovax Pharm reported a more than 25% year-on-year increase in export sales in monetary terms during the first half of 2025 compared to the same period of 2024.

By the end of the year, despite the strengthening of the ruble, the company expects further export growth and aims to exceed RUB 3 billion in export revenues. The growth will be driven by the retail product portfolio, as well as by the launch of international deliveries of the influenza vaccines Grippol^® Plus and Grippol^® Quadrivalent for the 2025–2026 epidemic season. Petrovax Pharm is one of the leading Russian exporters of influenza vaccines^[1], supplying over 6.5 million doses annually to international markets.

The main growth drivers in the first half of 2025 were the retail products Polyoxidonium^® (up 34% in ruble terms) and Longidaza^® (up 23%)^[2]. The company exports its products not only to the EAEU member states but also to the European Union. Exports of Polyoxidonium^® to Slovakia have been ongoing for more than 15 years, and per capita consumption of the product there is four times higher than in Russia.

Currently, Petrovax Pharm’s export portfolio includes 12 brands, which are supplied to 12 countries across the EU and EAEU.

Since the beginning of 2025, the company has further expanded its international footprint: Azerbaijan became a new market of presence, while shipments to Uzbekistan and Kazakhstan grew by 26% in volume (packages). In the near future, Petrovax Pharm plans to enter the markets of Egypt, Western and Southern Africa, and the Arab states.